@article{MAKHILLRJMS201812631769,
    title = {Clinical Evaluation of Intravitreal Bevacizumab in Patients with Macular Edema Secondary to Retinal Vein Occlusion: A 3‐Month Follow‐Up Study},
    journal = {Research Journal of Medical Sciences},
    volume = {12},
    number = {6},
    pages = {98-104},
    year = {2018},
    issn = {1815-9346},
    doi = {makrjms.2018.98.104},
    url = {https://makhillpublications.co/view-article.php?issn=1815-9346&doi=makrjms.2018.98.104},
    author = {Anoop},
    keywords = {Intraocular bevacizumab, Macular edema, Retinal vein occlusion, Branch retinal vein occlusion, Central retinal vein occlusion, Visual acuity, Central macular thickness, VEGF inhibition, Retinal vascular occlusion, Ophthalmology},
    abstract = {The study aimed to determine the anatomical and functional results of
intravitreal bevacizumab (IVB) in patients with macular edema due to
retinal vascular occlusion (RVO). The study was conducted at Department
of Ophthalmology of Era’s Lucknow Medical College and Hospitals. In this
retrospective observational study, 98 Patients with branch or central
BRVO (BRVO/CRVO) and ME were enrolled. Bevacizumab (1.25 mg) was
injected into the vitreous of all patients and they were followed for three
months. Best‐corrected visual acuity (BCVA) quantified with Log MAR and
central macular thickness (CMT) with optical coherence tomography
(OCT) were measured at baseline, 1 month and 3 months. Results were
analyzed within BRVO and CRVO groups and with reinjection frequency.
The average age was 58.3±12.4 years and 55.1% were male. BRVO was
detected in 63.3% and CRVO in 36.7% of patients. Mean CMT decreased
significantly from a baseline level (480±110 μm) to 1 (275±95 μm) and 3
months (260±85 μm) after treatment (p<0.001). The mean BCVA
significantly increased from 1.1±0.4 LogMAR at baseline to 0.65±0.3 and
0.60±0.35 at 1 and 3 months, respectively (p<0.001). 3 months BRVO
patients had better anatomic and visual improvements compared to
CRVO patients (p<0.01, ). The result was better when patients received
two or more injections than when they received only one injection.
Bevacizumab given intravitreally is safe and effective in reducing macular
edema and improving VA in patients with RVO. The early and repetitive
course has a better result, especially in cases of BRVO. This study results
corroborate the value of bevacizumab as one of the most economical
treatment modality in RVO disease.}
    }